ZTS vs. BMY, PFE, ABBV, GSK, REGN, VRTX, TAK, SNY, GMAB, and ABT
Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Bristol-Myers Squibb (BMY), Pfizer (PFE), AbbVie (ABBV), GSK (GSK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Sanofi (SNY), Genmab A/S (GMAB), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.
Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Zoetis currently has a consensus target price of $211.75, suggesting a potential upside of 21.89%. Bristol-Myers Squibb has a consensus target price of $60.00, suggesting a potential upside of 36.02%. Given Bristol-Myers Squibb's higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.
Bristol-Myers Squibb received 180 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.82% of users gave Zoetis an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Zoetis has a net margin of 27.38% compared to Bristol-Myers Squibb's net margin of -13.50%. Zoetis' return on equity of 50.34% beat Bristol-Myers Squibb's return on equity.
Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.4%. Zoetis pays out 33.3% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Bristol-Myers Squibb had 27 more articles in the media than Zoetis. MarketBeat recorded 44 mentions for Bristol-Myers Squibb and 17 mentions for Zoetis. Bristol-Myers Squibb's average media sentiment score of 0.58 beat Zoetis' score of 0.56 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
Zoetis has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Summary
Zoetis beats Bristol-Myers Squibb on 12 of the 20 factors compared between the two stocks.
Get Zoetis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
